Luke Halpern, Associate Editor

Clinical pharmacists Andrew Willeford and Laura Velazquez explore the paradigm shift in oHCM management, highlighting best practices for pharmacist-led clinical workflows in health-system practice.

Patients with CKD and GERD who initiated P-CABs had a 37% lower risk of needing renal replacement therapy.

Data from the STEP UP trial support semaglutide 7.2 mg as a well-tolerated option for patients who need greater weight reduction.

The commissioner's sudden departure leaves the agency navigating a crowded agenda of unresolved policy questions—many with direct implications for pharmacists and their patients.

Makary's 13-month tenure ends after clashes with the Trump administration over flavored vape approvals, mifepristone policy, and broader agency management.

Integrated pharmacist-led care models help to improve diabetes outcomes, expand CGM use, and reduce costs through proactive, multidisciplinary patient management.

Marilyn Bulloch, PharmD, discusses the persistent burden of hepatitis B, evolving adult vaccination recommendations, and how pharmacists can improve vaccine uptake through accessible, stigma-free patient counseling.

Pharmacy technicians are essential for navigating access barriers, addressing misconceptions, and supporting adherence in obesity care.

The ACACIA-HCM trial marks the first time a therapy has shown statistically significant improvements in exercise capacity and symptom burden in patients with non-obstructive hypertrophic cardiomyopathy.

Metabolic dysfunction-associated steatotic liver disease (MASLD) remains largely underdiagnosed and asymptomatic, creating major opportunities for pharmacists to drive early identification, lifestyle intervention, and metabolic risk management.

Pharmacy technicians are increasingly central to obesity care, supporting medication access, workflow efficiency, and patient engagement in ambulatory settings.

Joseph Saseen, PharmD; and Joel C. Marrs, PharmD, discuss key updates in the 2026 dyslipidemia guidelines and their implications for clinical and pharmacy practice.

The agency greenlit 4 Glas electronic nicotine delivery systems through the premarket tobacco product application pathway, a historic first that comes amid reported White House pressure on FDA Commissioner Marty Makary.

New findings presented at the World Congress of Nephrology detail how chronic kidney disease (CKD) drives progressive muscle loss and cognitive decline.

New CMS prior authorization timelines highlight major infrastructure gaps while underscoring the link between access, affordability, and medication adherence.

The interchangeable designation allows pharmacists to substitute Langlara for Lantus at the point of dispensing without prescriber intervention, a distinction that carries significant clinical and operational implications for pharmacy practice.

The agency's proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List signals that large-scale compounding of these agents has no regulatory future, and carries immediate implications for pharmacy practice.

The dextromethorphan-bupropion combination therapy targets NMDA and sigma-1 receptors, offering a first-in-class mechanism distinct from the only other approved agent for this indication.

Coordinated pharmacist-led outreach, e-consults, and continuous glucose monitoring support improve diabetes outcomes, increase guideline-based therapy use, and impact total cost of care.

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 1.3 billion people globally, driven by metabolic disease trends, highlighting urgent needs for earlier detection, prevention, and pharmacist-led intervention.

Integrated health plan–provider collaboration enables pharmacists to drive proactive diabetes management, improve adherence, and expand access to CGM and lifestyle support.

2026 dyslipidemia guideline updates highlight earlier risk-based lipid management, expanded biomarker use, and a growing pharmacist role in cardiovascular prevention.

Two studies presented at the World Congress of Nephrology 2026 highlight nonpharmacological strategies that may help preserve kidney function in at-risk populations.

Large real-world analysis supports potential renal and survival benefits of urate-lowering therapy in patients with chronic kidney disease and hyperuricemia.

Extended data from ACHIEVE-4 reinforce the durability of oral GLP-1 receptor agonist therapy, with implications for long-term diabetes management and pharmacist-led care.

Dupilumab becomes the first biologic approved for children aged 2 to 11 years with uncontrolled chronic spontaneous urticaria, marking a significant expansion in treatment options and pharmacist-led care considerations.

A large multicohort analysis highlights obesity as a modifiable risk factor for severe infectious outcomes, reinforcing the pharmacist’s role in prevention, vaccination, and chronic disease management.

The approval of doravirine and islatravir marks a new 2-drug, once-daily oral option for HIV-1 management, with implications for treatment simplification, adherence, and pharmacist-led antiretroviral care.

A new study supports the use of PREVENT equations in routine clinical practice, reinforcing their role in cardiovascular risk assessment and pharmacist-led prevention strategies.

A federal directive to expedite FDA review and expand research pathways for psychedelic therapies signals a potential shift in mental health treatment.